TY - JOUR
T1 - Various types of electrochemical biosensors for leukemia detection and therapeutic approaches
AU - Chupradit, Supat
AU - KM Nasution, Mahyuddin
AU - Rahman, Heshu Sulaiman
AU - Suksatan, Wanich
AU - Turki Jalil, Abduladheem
AU - Abdelbasset, Walid Kamal
AU - Bokov, Dmitry
AU - Markov, Alexander
AU - Fardeeva, Irina N.
AU - Widjaja, Gunawan
AU - Shalaby, Mohammed Nader
AU - Saleh, Marwan Mahmood
AU - Mustafa, Yasser Fakri
AU - Surendar, A.
AU - Bidares, Ramtin
N1 - Publisher Copyright:
© 2022 Elsevier Inc.
PY - 2022/10/1
Y1 - 2022/10/1
N2 - Leukemia often initiates following dysfunctions in hematopoietic stem cells lineages. Various types of leukemia, including acute lymphoblastic leukemia (ALL), chronic myelogenous leukemia (CML), acute promyelocytic leukemia (APL), and human T-cell leukemia/lymphoma virus type 1 (HTLV-1) can thus call for different diagnosis and treatment options. One of the most important subjects in leukemia is the early detection of the disease for effective therapeutic purposes. In this respect, biosensors detecting the molecules of deoxyribonucleic acid (DNA) as analytes are called genosensors or DNA biosensors. Electrochemical sensors, as the most significant approach, also involve reacting of chemical solutions with sensors to generate electrical signals proportional to analyte concentrations. Biosensors can further help detect cancer cells in the early stages of the disease. Moreover, electrochemical biosensors, developed based on various nanomaterials (NMs), can increase sensitivity to the detection of leukemia-related genes, e.g., BCR/ABL as a fusion gene and promyelocytic leukemia/retinoic acid receptor alpha (PML/RARα). Therefore, the present review reflects on previous studies recruiting different NMs for leukemia detection.
AB - Leukemia often initiates following dysfunctions in hematopoietic stem cells lineages. Various types of leukemia, including acute lymphoblastic leukemia (ALL), chronic myelogenous leukemia (CML), acute promyelocytic leukemia (APL), and human T-cell leukemia/lymphoma virus type 1 (HTLV-1) can thus call for different diagnosis and treatment options. One of the most important subjects in leukemia is the early detection of the disease for effective therapeutic purposes. In this respect, biosensors detecting the molecules of deoxyribonucleic acid (DNA) as analytes are called genosensors or DNA biosensors. Electrochemical sensors, as the most significant approach, also involve reacting of chemical solutions with sensors to generate electrical signals proportional to analyte concentrations. Biosensors can further help detect cancer cells in the early stages of the disease. Moreover, electrochemical biosensors, developed based on various nanomaterials (NMs), can increase sensitivity to the detection of leukemia-related genes, e.g., BCR/ABL as a fusion gene and promyelocytic leukemia/retinoic acid receptor alpha (PML/RARα). Therefore, the present review reflects on previous studies recruiting different NMs for leukemia detection.
KW - Biosensor
KW - Electrochemical
KW - Leukemia
KW - Nanomaterial
UR - http://www.scopus.com/inward/record.url?scp=85130952782&partnerID=8YFLogxK
U2 - 10.1016/j.ab.2022.114736
DO - 10.1016/j.ab.2022.114736
M3 - Review article
C2 - 35588855
AN - SCOPUS:85130952782
SN - 0003-2697
VL - 654
JO - Analytical Biochemistry
JF - Analytical Biochemistry
M1 - 114736
ER -
